We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+2.09%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.09B
AUM Growth
-$133M
Cap. Flow
+$26.4M
Cap. Flow %
0.52%
Top 10 Hldgs %
35.29%
Holding
140
New
25
Increased
26
Reduced
29
Closed
16

Top Buys

Rank Stock Value
1
ELVN icon
Enliven Therapeutics
ELVN
+$161M
2
BIIB icon
Biogen
BIIB
+$68.3M
3
BAX icon
Baxter International
BAX
+$66.2M
4
LLY icon
Eli Lilly
LLY
+$62.7M
5
APLS
Apellis Pharmaceuticals
APLS
+$52.5M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$117M
2
PFE icon
Pfizer
PFE
+$71.4M
3
UNH icon
UnitedHealth
UNH
+$50.4M
4
NTRA icon
Natera
NTRA
+$46.7M
5
ETNB
89bio
ETNB
+$46.6M

Sector Composition

Rank Sector Weight
1 Healthcare 96.7%
2 Industrials 0.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BAX icon
76
CALL
Baxter International
BAX
$12.8B
$14.2M 0.28%
+350,000
New +$14.8M
GHRS icon
77
GH Research
GHRS
$1.89B
$13.3M 0.26%
1,659,015
+36,955
+2% +$340K
FOLD
78
DELISTED
Amicus Therapeutics
FOLD
$13M 0.25%
1,171,000
+655,000
+127% +$8.07M
ALXO icon
79
ALX Oncology
ALXO
$261M
$13M 0.25%
2,871,000
– –
FUSN
80
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$11.8M 0.23%
3,122,770
-102,000
-3% -$402K
IMA
81
ImageneBio Inc
IMA
$64M
$11M 0.22%
265,514
+21,019
+9% +$966K
GDRX icon
82
GoodRx Holdings
GDRX
$1.07B
$10.6M 0.21%
1,700,000
+1,312,433
+339% +$7.32M
VERA icon
83
Vera Therapeutics
VERA
$2.32B
$10.6M 0.21%
+1,362,400
New +$10.5M
BCAB icon
84
BioAtla
BCAB
$5.63M
$10.3M 0.2%
77,220
+70,573
+1,062% +$12.7M
SRPT icon
85
CALL
Sarepta Therapeutics
SRPT
$1.62B
$10.3M 0.2%
+75,000
New +$9.73M
PASG icon
86
Passage Bio
PASG
$14.9M
$8.55M 0.17%
446,600
– –
DMRA
87
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.78B
$8.14M 0.16%
163,637
– –
ORIC icon
88
Oric Pharmaceuticals
ORIC
$1.16B
$7.83M 0.15%
1,374,468
-233,100
-15% -$1.22M
XBI icon
89
CALL
State Street SPDR S&P Biotech ETF
XBI
$10B
$7.62M 0.15%
+100,000
New +$8.3M
PTGX icon
90
Protagonist Therapeutics
PTGX
$8.81B
$6.92M 0.14%
+301,000
New +$5.06M
LSB
91
DELISTED
LakeShore Biopharma
LSB
$6.88M 0.14%
+429,846
New +$21.8M
VSTM icon
92
Verastem
VSTM
$519M
$6.85M 0.13%
1,375,270
– –
IMTX icon
93
Immatics
IMTX
$1.18B
$6.54M 0.13%
+947,248
New +$7.75M
IVVD icon
94
Invivyd
IVVD
$168M
$6.32M 0.12%
5,270,400
– –
CRVS icon
95
Corvus Pharmaceuticals
CRVS
$1.1B
$6.32M 0.12%
6,943,654
– –
CGEM icon
96
Cullinan Oncology
CGEM
$1.03B
$6.19M 0.12%
605,387
-31,900
-5% -$352K
NTLA icon
97
Intellia Therapeutics
NTLA
$1.49B
$6.14M 0.12%
+164,627
New +$6.46M
MRTX
98
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$5.58M 0.11%
+150,000
New +$6.75M
MREO
99
Mereo BioPharma
MREO
$50.9M
$5.48M 0.11%
7,747,891
-2,857,631
-27% -$2.57M
HZNP
100
PUT
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$5.46M 0.11%
+50,000
New +$5.53M
2 3
4
5 6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q1 2023 Portfolio in Review

As of Q1 2023, OrbiMed held 140 positions worth $5.09B, down 2.6% from $5.23B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

OrbiMed's Q1 2023 filing shows 25 new, 26 increased, 29 reduced and 16 closed positions. Its largest new stake was Baxter International: 1,562,000 shares worth $63.4M. The largest sale was Seagen Inc. Common Stock, an estimated $117M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Industrials.

  • OrbiMed's largest Q1 2023 buy was Baxter International: 1,562,000 shares worth $63.4M.
  • OrbiMed added most to Enliven Therapeutics in Q1 2023, an estimated $161M increase.
  • OrbiMed's biggest Q1 2023 reduction was UnitedHealth, cutting an estimated $50.4M.
  • OrbiMed fully exited Seagen Inc. Common Stock in Q1 2023, selling an estimated $117M.
  • OrbiMed's ten largest holdings make up 35% of its $5.09B portfolio in Q1 2023.
  • OrbiMed opened 25 new positions and closed 16 in Q1 2023.
  • OrbiMed's portfolio value fell 2.6% quarter-over-quarter to $5.09B.

Based on OrbiMed's 13F filing for Q1 2023, filed 15 May 2023.